Allergy Testing for Allergic Rhinitis

TITLE: Allergy Testing for Allergic Rhinitis
SOURCE: Grand Rounds Presentation, University of Texas Medical Branch, Dept. of Otolaryngology
DATE: September 26, 2007
RESIDENT PHYSICIAN: Michael Briscoe Jr., MD
FACULTY PHYSICIAN: Jing Shen, MD
SERIES EDITORS: Francis B. Quinn, Jr., MD

"This material was prepared by resident physicians in partial fulfillment of educational requirements established for the Postgraduate Training Program = of the UTMB Department of Otolaryngology/Head and Neck Surgery and was not intended for clinical use in its present form. It was prepared for the purp= ose of stimulating group discussion in a conference setting. No warranties, eit= her express or implied, are made with respect to its accuracy, completeness, or timeliness. The material does not necessarily reflect the current or past opinions of members of the UTMB faculty and should not be used for purposes= of diagnosis or treatment without consulting appropriate literature sources and informed professional opinion."

Introduction

Allergic rhinitis affects about 1/3 of the US population. Morbidity from th= is disease leads to decreased productivity, lost work/school days, and increas= ing costs of medical care and treatment. It is defined as inflammation of the nasal mucosal lining caused by = an exaggerated IgE mediated hypersensitivity to aeroallergens. Symptoms include rhinorrhea, nasal congestion, post nasal drip, sneezing, cough, itchy nose and eyes, and fati= gue. It is an important entity for the practicing otolaryngologist because many of these patients have failed medi= cal management. In order to treat= these patients, allergy testing may need to be performed in order to start vaccine immunotherapy.

Allergy testing has been around for many years.<= span style=3D'mso-spacerun:yes'> In 1872 pollen was identified as t= he causative factor for fall hay fever, and Blakely performed first skin test = with pollen extract. In 1912, the = first intradermal test was performed by Schloss. In the 1920’s skin prick testing was introduced by Lewis and Grant. 1935 Hansel began using serial dil= ution testing (1:5 dilutions with endpoint testing) and Rinkel perfected serial endpoint testing in the 1940’s. Recently, Krouse introduced modified quantitative testing. In order to understand the need for allergy testing, a brief review of immunology and how it affects allergic rhinitis is needed.

Review of Immunology in Allergic Disease:

Allergy represents an exaggerated immunologic re= sponse to an otherwise innocuous agent, which causes harm to the host. The inciting agent is known as the allergen. There are four type= s of hypersensitivity reactions, which were originally characterized by Gell and Combs.

Type I: Immediate IgE mediated hypersensi= tivity causes rapid degranulation of mast cells with pro-inflammatory cytokines. IgE binds to mast cells via a high affinity Fc receptor. Charact= erized by early phase, within minutes, and late phase, hours after initial response. Examples include al= lergic rhinitis, food allergy, and allergic or atopic asthma.

Type II:= Antibody mediated, in which antibodies bind to cells and causes dama= ge or impairment of function. Ex= amples include transfusion reactions, hemolytic anemias, hyperacute graft rejection Myasthenia Gravis and Goodpasture’s syndrome.

Type III: Immune complex mediated occurs when= IgG or IgM binds with antigens, and the complexes are deposited in tissues, especially small vessels. Onc= e in the tissues, damage occurs secondary to complement activation. Examples include serum sickness, glomerulonephritis, and arthritis.

Type IV:= T-cell mediated (delayed hypersensitivity), on first exposure, T cel= l is sensitized. On subsequent exposures, the allergen is detected on the surface of target cells and these cells are lysed by T cells. Examples include contact dermatitis, granulomatous diseases.

Allergic diseases important to the otolaryngolog= ist are allergic rhinitis and food allergy, both of these are IgE mediated (type I). Early phase ranges from a minimal wheal and flare reaction to anaphylaxis. The response is characterized by vasodilation, vascular leakage, smooth muscle spasm and glandular secretions. These changes occ= ur within 5 to 30 minutes and tend to subside within 60 minutes. Late phase reactions occur 2 to 8 = hours after initial exposure and last for several days. Migration of eosinophils, neutroph= ils, basophils, and CD4+ T cells occurs and mucosal tissue damage also occurs.

Cells Important for Allergic Response

B cells are the only lymphocytes that can produce antibodies. They matu= re in the bone marrow, and are responsible for humoral immunity. They produce IgA, IgD, IgE, IgG an= d IgM antibodies. IgA is a dimer th= at is predominantly found in secretions. IgD is produced by naïve B cells, and may be involved in antigen-induced lymphocyte proliferation.&= nbsp; IgE is found in immediate hypersensitivity and helminthic infections. IgG is the major antibody of secondary responses. It is active against viruses, bacteria, and fungi, the only immunoglobulin that crosses the placenta, and fixes complement by the classic pathway. IgM is a pentamer and the predomin= ant antibody in the early immune response.&nbs= p; Naïve B cells produce IgM and IgD, and undergo isotype class switching under the influence of T cells (T_H2) and certain antig= ens.

T cells travel from the bone marrow and m= ature in the thymus. They recognize peptide fragments of foreign proteins bound to self-major histocompatibilty= complex (MHC) in other cells in the body. T helper cells (CD4+) recognize antigens found on MHC class II molecules on antigen presenting cells. TH1 cells are involved in phagocyte mediated defenses against intracellular microbial infections. TH2 cells secrete IL-4, IL-5, IL-9, IL-10, and IL-13. TH2 cells down regulate TH1 cells,= and induce B cell isotype switching. Catalytic T lymphocytes (CD8+) recognize antigens on MHC I molecules= .

Antigen presenting cells include monocyte= s, macrophages, dendritic cells, and B cells.= Process antigens and present peptides on their cell surface via MHC molecules that activate T cells.

Mast Cells and Basophils are the major ef= fector of type I mediated hypersensitivity. IgE cross-links these cells causing rapid degranulation of their contents. Activation of these= cells leads to release of chemokines by three different pathways. 1) immediate release of histamine, heparin, proteases, and TNF alpha. This leads to vasodilatation and leaky vessels, as well as changes in the endothelium that allows migration other inflammatory cells. 2) enzymatic modification of arach= idonic acid into prostaglandins and leukotrienes, within 1 or 2 hours. 3) Synthesis and secretion of IL-3, IL-4, IL-5, and GM-CSF, which recru= it other inflammatory cells and are responsible for the late phase of an aller= gy attack.

IgE Mediated hypersensitivity

The pathogenesis of a type I hypersensitivity re= action starts with IgE antibody production, also called the sensitization phase. Antigen is presented by antigen presenting cells to CD4+ Th2 cells. The activated Th2 cells then produces a cluster of cytokines, includ= ing IL-3, IL4, IL-5, IL-13 and GM-CSF. IL-4 is absolutely essential for turning on the IgE –producing= B cells and for sustaining the development of Th2 cells. IL-3 and IL-5 promote the survival= of eosinophils. IgE antibodies produced by B cells quickly attach to mast cells and basophils. When mast cells and basophils are exposed to antigen again, antigen binds to the IgE antibodies on the surfac= e of these cells. Multivalent anti= gen causes cross-linking of IgE antibodies, which activates cell degranulation = with discharge of preformed mediators and de novo synthesis of mediators. These mediators are responsible fo= r the observed increased vascular permeability, increased mucus secretion, and sm= ooth muscle contraction in the allergic reaction. These mediators also have chemotac= tic properties. Eosinophils, neutrophils, and monocytes are recruited and release additional waves of mediators. The recruited cells amplify and sustain the inflammatory response without additional exposure to the triggering antigen. This = is the late phase reaction.

Allergic Rhinitis

Inflammation of the membrane lining the nose sec= ondary to hypersensitivity to aeroallergens, characterized by rhinorrhea, sneezing, pruritis, congestion, post nasal drip and associated conjunctival, otologic= or pharyngeal inflammation. Thes= e symptoms can be episodic, seasonal or perennial.&nb= sp; Severity ranges from mild, to seriously debilitating with excess day= s of missed school or work. Risk f= actors include family history of atopy, serum IgE > 100 IU/ml before age six, higher socioeconomic class, exposure to aeroallergens, presence of positive allergy skin prick test.

Differential Diagnosis

I. = &nb= sp; Infectious

II. = NARES (Nonallergic rhinitis with eosinophilia

III. = Vasomotor rhinitis

IV. = Other rhinitis syndromes

a. = Ciliary dyskinesia

b. Exercise induced

c. = Atrophic rhinitis

d. Hormonally induced

&nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; i. &nb= sp; Hypothyroidism

&nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; ii. &n= bsp; Pregnancy

&nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; iii. &= nbsp; Oral contraceptives

&nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; iv. &n= bsp; menstrual

e. = Drug induced

&nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; i. &nb= sp; Rhinitis medicamentosa

&nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; ii. &n= bsp; Antihypertensive therapy

&nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; iii. &= nbsp; Aspirin

&nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; iv. &n= bsp; NSAIDs

f. = Reflex induced

&nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; i. &nb= sp; Gustatory

&nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; ii. &n= bsp; Chemical or irritant induced

&nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; iii. &= nbsp; Posture reflexes

&nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; iv. &n= bsp; Nasal cycle

&nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; v. &nb= sp; Emotional factors

g. = Occupational

V. = Structural/mechanical

a. = Deviated septum

b. Turbinate hypertrophy

c. = Adenoid hypertrophy

d. Foreign body

e. = Choanal atresia

f. = Nasal tumors

VI. = Inflammatory

a. = Wegener’s granulomatosis

b. Sarcoidosis

c. = Midline granuloma

d. Sjogren’s syndrome

e. = SLE

f. = Nasal polyposis

VII. = Cerebrospinal fluid leak

History and Physical Exam

It is important to illicit timing, severity, ons= et, duration, and effect on daily living. Many patients will have an idea of what triggers their symptoms and = the seasonality of symptoms. Environmental questions should include home, work school/daycare exposures, and exposure to tobacco. Past nasal trauma, positive family history, current and past treatme= nts, should al be included in history.

Physical exam includes a complete head and neck exam. Special attention is pa= id to the patient’s general appearance.&nb= sp; Facial pallor, allergic shiners, nasal crease, mouth breathing, and clubbing of the fingers can signify allergic rhinitis. Examine the eyes for conjunctiviti= s and Dennie-Morgan lines, accentuated lines or folds below the margin of the inferior eyelid. The nose may reveal polyps, enlarged turbinates, presence of mucus or purulent drainage, septal deviation or blood. Th= e exam of the oropharynx may reveal tonsillar hypertrophy or cobblestoning. The ears must be examined for abnormalities to the middle ear, or tympanic membrane. The neck should be examined for lymphadenopathy and thyroid enlargement.&n= bsp; Auscultation of the lungs is necessary to assess for wheezing, or ot= her signs of asthma, and the skin should be examined for eczema, dryness, or dermatographism.

Pathophysiology of Allergic Rhinitis

Atopic subjects inherit the propensity to produce IgE-mast cell lymphocyte immune responses.= Exposure to low levels of aeroallergens for prolonged periods of time leads to presentation of epitopes being presented to CD4+ cells by APC’s. These CD4+ cells= then secrete IL-3, IL-4, IL-5, GM-CSF and other cytokines. This promotes proliferation of pla= sma cells that produce IgE, mast cells, and infiltration of nasal mucosa and eosinophilia.

Early response with continued expo= sure, IgE coated mast cells infiltrate the nasal mucosa, and are activated when t= hey encounter the allergen. Mast = cells release, histamine, heparin, tryptase, kinase, chymase and other chemokines= . Arachidonic acid is broken down to prostaglandins and leukotrienes that stimulate leaky vessels and nasal edem= a, release of mucus, and dilate arteriole-venule anastomoses causing occlusion= of nasal air passages. Sensory n= erves are stimulated and relay sensations of nasal itching and congestion, and initia= te the sneeze reflex.

Late response occurs 2 to 11 hours= after initial exposure. Mast cell chemokines affect the endothelium promoting VCAM and E-selectin expression. These molecules a= llow circulating leukocytes to stick to the endothelium. IL-5 attracts eosinophils, neutrop= hils, basophils, T cells, and macrophages. Over the course of 4 to 6 hours, these cells release even more chemo= kines. Eosinophils release major basic pr= otein, eosinophil cationic protein, hypochlorate, and leukotrienes, which cause inflammation and damage seen in chronic allergic reactions.

Allergy Testing

Screening tests should have the following characteristics: 1) be rapid, efficient, and cost effective method to assess allergy. 2) Antigens should be representative of what the patient may encounter, and should be geographica= lly based. Most allergic individu= als will react to common antigens via in vivo or in vitro techniq= ues. Negative result usually requires no additional testing. Positive = result requires further testing of other antigens in the group or family. There may be some cross-reactivity, especially with molds. Also, = they should test for 12 to 14 antigens, (pollen, mold, weeds, dust mite, animal dander)

Nasal smear used to differentiate allergic rhinitis and NARES, from other forms of rhinitis. Typically find eosinophilia, but i= ts absence does not rule out allergic rhinitis. May find neutrophils in smear as w= ell.

Skin testing is the most widely us= ed form of allergy testing. 2003= AAOA guidelines for allergy testing state:

· The goal of testing is to identify antigens = to which patients are symptomatically reactive and to quantify the sensitivity= if immunotherapy is planned

· There are a variety of acceptable techniques= :

<= span style=3D'mso-list:Ignore'>o&nb= sp; Prick testing, intradermal testing, intrader= mal dilutional testing, and in vitro testing

· Allergy care shall be directed by a trained = and competent physician who regularly participates in the care

· Members shall practice in an ethical and fiscally responsible manner

Prick/scratch testing (SPT) is a superficial skin reaction that does not penetrate dermis. It is highly specific, sensitive, convenient and safe. It does require a positive (histamine) and negative (saline) control. Disadvantages include: patient discomfort, intertester variability, and nonstandaridized allergen extracts= , as well as different interpretation scales.&n= bsp; An example of this is the multitest II. This introduces 6 to 10 antigens p= lus the positive and negative control using an instrument that scratches the skin. A test is positive if t= here is a wheal and flare reaction which is greater than or equal to the histami= ne control.

Intradermal testing (IT) a dilute antigen extract is injected into the dermis, and a superficial wheal forms. After ten minutes, the= wheal is measured again to see if there was any progression. If the diameter of the wheal has increased by 2mm or greater, then a positive response has occurred. This causes relatively minimal pat= ient discomfort. Disadvantages inc= lude higher risk of anaphylaxis, time intensive and possible false positive.

Intradermal dilutional testing/Set endpoint titration (IDT/SET) Intradermal tes= ting utilizing serial dilutions to quantify degree of sensitivity to specific antigen. Very labor intensive= and uncomfortable to patient due to multiple sticks. Wheal measures similar to intrader= mal testing. 1^st dilut= ion that causes a wheal of 2mm, with progression of this wheal by another 2mm (confirmatory wheal). This ty= pe of testing is important for determining the initial concentration used for immunotherapy.

Modified quantitative testing (MQT) a hybrid of skin prick and IDT. Skin prick determines an approximate range of sensitivity, followed by a single intradermal test to further identify the level of sensitivity and quantify = the allergic response.

In Vitro testing RAST (radioallergosorbent testing) RAST is a radioimmunoassay test developed in = the late 60's for the detection of specific serum IgE antibodies. Initial studi= es demonstrated a 96% efficiency, sensitivity and specificity. The modified RAST is the form = now used, introduced by Fadal and Nalebuff in 1977 with the advantages of incre= ased test sensitivity without a loss in specificity.

Soluble allergens bound to solid phase support (= paper disc) to create a stable immunosorbent media. The paper disc is incubated w= ith the test sera, specific IgE antibody will bind to the solid phase allergen.= The paper disc is then washed to remove all unbound sera and IgE. The disc is then exposed to rabbit anti-human IgE antibodies which are radiolabeled. It interacts with the Fc determinant portion on human IgE bound to the solid phase allergen. The unbound anti-IgE is washed off= the disc and the disc is then quantified by a scintillation counter.

This test should be used when there are contraindications to skin testing. These include children that can not tolerate skin testing, patients = on antihistamines, patients with dermatographism, and those taking beta blocke= rs (may be impossible to treat anaphylaxis).

Comparing the tests

Efficacy

Gungor et al found that skin prick testing corre= lates with RAST and SET 81-89% of the time depending on the antigen. Skin prick testing is fast, inexpe= nsive, and has only mild patient discomfort. However, there are false negatives, and this type of testing cannot = be performed in patients who are on antihistamines.

Simons et al compared Multitest II (skin prick) = to IDT. Found that patients were positive to more antigens with IDT. This may be because IDT is more sensitive or there could be more fal= se positives. However, he did fi= nd that multitest II did correlate with the IDT endpoint. In 2006 McKay performed a retrospe= ctive chart review of patients with a positive IDT after negative skin prick test. Certain antigens were m= ore likely to have a positive IDT after negative skin prick (dust mite, cockroa= ch, fulsarium rough marsh elder, and ragweed).= He concluded that this could be from glycerin reaction, or true posi= tive due to the increased sensitivity of IDT.&n= bsp; In order to know for sure, he recommended nasal provocation testing.=

2007 Peltier et al performed a prospective study= using five antigens to compare MQT, SPT, and IDT. Found a 77% concordance rate betwe= en MQT and IDT, wheal size from SPT is predictive of IDT endpoint, and that MQT is nearly as effective as IDT for starting doses of immunotherapy.

Cost

2003 Shah et al compared multitesting with SET (= MQT) versus IDT/SET. Concluded that multitesting is a cost effective screening test. MQT can be used to find the starti= ng doses for immunotherapy and is one third less costly and time consuming then IDT/SET alone.

2006 Seshul et al defends the use of IDT/SET on = an overall cost effectiveness. W= ith IDT, the highest dose to safely start immunotherapy is known. Thus this is the starting dose for immunotherapy. With SPT, he f= ound that it correlated poorly to endpoint titration. This would cause a lower starting = dose, with more time and cost to reach the maintenance doses needed for successfu= l immunotherapy.

Adjuvant testing&nb= sp;

Nasal Endoscopy allows direct visualization of nasal mucosa. It allows for accurat= e, site specific nasal smears and is important in ruling out other nasal pathology.

Acoustic rhinometry measures cross sectio= nal area and intranasal cavity volume by bouncing sound signals on the nasal structures. Measurements are = taken before and after decongestion. Nasal provocation takes this one step further, by introducing an allergen via a metered dose spray, then taking measurements. Cross sectional area 2, correspond= s with the anterior border of the inferior turbinate, is the best site for assessi= ng sensitivity to an allergen (Uzzamann et al). This is still an experimental test= , but some Allergists have pushed for its use in the evaluation of allergic rhinitis. Dykewicz et a= l 1998 Joint Task Force on Practice parameters in Allergy, Asthma and Immunology c= ited that nasal provocation has a role in workplace allergies. Also, it may play a role in deciph= ering whether IDT has higher sensitivity or higher rate of false positives than S= PT.

Treatment

Environmental measures should be taken by= all people that suffer from allergic rhinitis.= This includes avoidance of specific allergen, dehumidifiers, HEPA filters, special linens, weekly laundering of linens in hot water, frequent cleaning of household furniture, and minimizing carpet. For those with pets, they can cons= ider removing pet from the home, the bedroom, and should wash the pet weekly.

Medical treatment is the mainstay of ther= apy for allergic rhinitis. There = are many different classes of medications that can be used alone or in combination.

Nasal saline is an inexpens= ive treatment that is believed to cleanse the nasal mucosa of allergens.

Mast cell stabilizers such as crom= olyn sulfate act by decreasing the release of mast cell contents. It is fairly safe, but must be use= d four times per day and can not be used as a rescue medication.

Deconges= tants work by vasoconstriction, which leads to decreased edema and increased nasal patency. Topical therapies su= ch as oxymetazoline and phenylephrine provide quick relief, but can lead to tachyphylaxis and rhinitis medicamentosa with prolonged use. Oral medicines such as pseudoephed= rine are also useful, but many over the counter medications are using it less of= ten due to its significant side effects. These side effects include hypertension, tachyarrhythmia, wakefulnes= s, and urinary retention.

Antihistamines decrease symptoms of sneezing, itching, and edema by blocking the H1 receptor. Diphendydramine (benadryl) is the = most well known drug in this class. It has H1 receptor blockade, peripheral and central, as well as anticholinergic effects. Its central H1 activ= ity causes sedation, and its anticholinergic effects include dry oral/nasal muc= osa, urinary retention, memory impairment, and blurred vision. Due to its side effect profile, se= cond generation antihistamines were developed.&= nbsp; Cetirizine, loratidine, desloratidine, and fexofenadine are oral preparations, and azelastine is topical.&n= bsp; These are also known as non-sedating antihistamines, and are free of anticholinergic effects.

Leukotriene receptor antagonists b= lock the late phase of the allergic response.&n= bsp; Montelukast is approved for seasonal allergic rhinitis and is useful= in abating sneezing and nasal congestion.&nbs= p; Higher efficacy in patients with Samter’s triad because of the= ir increased production of leukotrienes.

Intranasal steroids should be firs= t line therapy for allergic rhinitis. All of the drugs used in the US for allergic rhinitis have a good safety profile, and high efficacy, when u= sed regularly. Many people prefer= oral to intranasal medications, or cannot tolerate associated epistaxis or dry mucosa. Also, there are conce= rns about growth suppression in children, and decreased bone density.

Immunotherapy should be considered= for patients with evidence of specific IgE antibodies to clinically relevant allergens. It is an effective treatment for allergic rhinitis, asthma, and hymenoptera stings. The decision to begin immunotherapy depends on the severity of symptoms, and their resistance to environmental = and medical interventions. Also, = some patients may want to avoid medication side effects, costs, and long term use and are good candidates for immunotherapy.= Immunotherapy may also prevent the development of asthma in children with allergic rhinitis.

Successful immunotherapy is associated with a sh= ift from TH2 to TH1 CD4+ cells, immunologic tolerance, increases in allergen-specific IgG blocking antibodies, and variable levels of specific = IgE. In order to have successful immuno= therapy, the specific allergen must be elucidated and a standardized vaccine should = be made. Weekly injections are continued with elevation of allergen dose until a maintenance dose is met.<= span style=3D'mso-spacerun:yes'> At this time, the injections will = need to continue for at least a total of three to five years. With immunotherapy, comes the risk= of anaphylaxis. To reduce this r= isk, an assessment of the patient’s general medical condition is necessary, i.e. history of asthma. Physi= cians should be trained in and prepared for treating anaphylaxis.

Conclusion

Allergic rhinitis plays a major role in the live= s of millions of Americans. As otolaryngologists, we will see many patients with this disease or diseases = that mimic it. We commonly prescri= be medications for allergic rhinitis without knowing the inciting antigen or antigens. Allergy testing can complete the picture for the physician and can play a role in the treatment strategies used to combat this disease.&nb= sp; Many of us do not receive this training in residency, and allergy testing can be somewhat of a mystery. Allergy testing plays a key role in immunotherapy, which is a viable alternative to medical management. Skin prick testing remains the most used test because of its ease of use, and its rapid results. It remains a great screening tool for allergic disease. Intradermal testing is slightly mo= re invasive and does not yield much more useful information. In contrast, intradermal dilutional testing and modified quantitative testing are useful when a screening test = is positive because they yield more information for starting doses of immunotherapy. RAST is also an integral part of a= llergy testing when contraindications to skin/dermal testing exist. There are still questions to be answered. In the future, we m= ay use a combination of in vivo and in vitro techniques in addition = to acoustic rhinometry or nasal provocation.&= nbsp; Many of the antigens are currently under investigation to decipher w= hich method of testing is the most sensitive and specific. Knowledge of allergy testing and immunotherapy is essential for all Otolaryngologists.

Bibliography

Dykewicz, <= st1:State w:st=3D"on">MS and S Fineman editors. “Diagnosis and management of rhinitis: Complete Guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma And Immunology.” Annals Allergy, Asthma, and Immunology(1998); Vol. 81, 478-518.

Gungor, A et al. “A comparison of skin endpoint titration and skin prick testing in the diagnosis of allergic rhinitis.” ENT – Ear, Nose, and Throat Journal (Jan 2004); Vol 83:1, 54-60.

Krouse JH and RL Mabry. “Skin testing = for inhalant allergy: Current strategies.” Otolaryngology Head and Neck Surgery Supplement (Oct 2003) Vol. 129:4

Li, JT and RF Lockey et al. “Allergen Immunotherapy: a practice parameter.” Annals Allergy, Asthma, and Immunology; Volume 90, Jan 2003; 1-40.

Mabry, RL, BJ Ferguson and JH Krouse editors= . Allergy: The Otolaryngologist’s Approach. The American Academy of Otolaryngologic Allergy 2005.

McKay SP, et al. “Intradermal positivity after negative skin prick for inhalants.”&= nbsp; Otolaryngology Head and Neck Surgery (2006); Vol. 135, 232-235

Peltier, JC and MW Ryan. “Comparison of intradermal dilution testing, skin prick testing, and modified quantitative testing for common allergies.” Otolaryngology Head and Neck Surgery (2007); Vol.137,246-49

Rouse, D, DL Park and T Sanford. “Alle= rgy symptom response to intradermal testing&nb= sp; based immunotherapy: A retrospective study of clincal practice.̶= 1; Otolaryngology

Head and Neck Surgery (2004); Vol 131, 220-2= 4. Seehul et al. “Use of intradermal dilutional testing and skin prick testing: Clinical relevance and cost efficiency.” Laryngoscope 116: S= ept. 2006, 1530-1538

Shah, SB and IA Emmanuel. “Cost analysis of employing multi-test all= ergy screening to guide serial endpoint titration (SET) vs. SET alone.” Otolaryngology Head and Neck Surge= ry (July 2003) Vol 129:1, 1-4.

Simons, JP et al. “Comparison of Multi= -test II skin prick testing to intradermal dilutional testing.” Otolaryngol= ogy Head and Neck Surgery; Vol. 130:5; 536-44.

Uzzamann, A et al. “Acoustic rhinometr= y in the practice of allergy.” Annals Allergy, Asthma, and Immunology; Vol. 97, Dec 2006; 745-752

Wood, RA et al. “A comparison of skin = prick tests, intradermal skin tests and RASTs in the diagnosis of cat allergy.= 221; Journal of allergy and clinical immunolgy (May 1999) Vol 103:5 part 1, 773-779.